From bones to blood pressure, developing novel biologic approaches targeting the osteoprotegein pathway for pulmonary vascular disease

Pharmacology and Therapeutics

Volumn 169, Issue , 2017, Pages 78-82

  Dawson, Sarah ^a   Lawrie, Allan ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Biologics; Bone; Osteoprotegerin; Pulmonary hypertension; Therapeutics; Vascular

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; OSTEOPROTEGERIN; SEROTONIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; BIOLOGICAL PRODUCT;

APOPTOSIS; ATHEROSCLEROSIS; BLOOD PRESSURE; CANCER CELL; CELL MIGRATION; DISEASE SEVERITY; HUMAN; IN VITRO STUDY; LUNG; OSTEOCLASTOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROSTATE; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; PULMONARY ARTERY SMOOTH MUSCLE CELL; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; REVIEW; SPLEEN; SURVIVAL; TISSUE LEVEL; TUMOR CELL; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; DRUG DESIGN; DRUG EFFECTS; FAMILIAL PRIMARY PULMONARY HYPERTENSION; METABOLISM; MOLECULARLY TARGETED THERAPY; OSTEOCLAST; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ANIMALS; BIOLOGICAL PRODUCTS; BLOOD PRESSURE; DRUG DESIGN; FAMILIAL PRIMARY PULMONARY HYPERTENSION; HUMANS; MOLECULAR TARGETED THERAPY; OSTEOCLASTS; OSTEOPROTEGERIN; SEVERITY OF ILLNESS INDEX;

EID: 84996605642     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2016.06.017     Document Type: Review

References (54)

1. Avignon, A., Sultan, A., Piot, C., Elaerts, S., Cristol, J., Dupuy, A., Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care 28:9 (2005), 2176–2180.
2. Baud'huin, M., Duplomb, L., Teletchea, S., Lamoureux, F., Ruiz-Velasco, C., Maillasson, M., et al. Cytokine & growth factor reviews. Cytokine Growth Factor Rev 24:5 (2013), 401–409, 10.1016/j.cytogfr.2013.06.001.
3. Bekker, P.J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P.T., Dunstan, C.R., The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16:2 (2001), 348–360, 10.1359/jbmr.2001.16.2.348.
4. Bennett, B., Scatena, M., Kirk, E., Rattazzi, M., Varon, R., Averill, M., et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE −/− mice. Arterioscler Thromb Vasc Biol 26:9 (2006), 2117–2124.
5. Benslimane-Ahmim, Z., Poirier, F., Delomenie, C., Lokajczyk, A., Grelac, F., Galy-Fauroux, I., et al. Mechanistic study of the proangiogenic effect of osteoprotegerin. Angiogenesis 16:3 (2013), 575–593, 10.1007/s10456-013-9337-x.
6. Body, J.-J., Greipp, P., Coleman, R.E., Facon, T., Geurs, F., Fermand, J.-P., et al. A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97:S3 (2003), 887–892, 10.1002/cncr.11138.
7. Boyce, B., Xing, L., Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther, 9(Suppl. 1), 2007, S1, 10.1186/ar2165.
8. Bucay, N., Sarosi, I., Dunstan, C., Morony, S., Tarpley, J., Capparelli, C., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:9 (1998), 1260–1268.
9. Burton, D.G.A., Giles, P.J., Sheerin, A.N.P., Smith, S.K., Lawton, J.J., Ostler, E.L., et al. Microarray analysis of senescent vascular smooth muscle cells: a link to atherosclerosis and vascular calcification. Exp Gerontol 44:10 (2009), 659–665, 10.1016/j.exger.2009.07.004.
10. Callegari, A., Coons, M.L., Ricks, J.L., Yang, H.L., Gross, T.S., Huber, P., et al. Bone marrow- or vessel wall-derived osteoprotegerin is sufficient to reduce atherosclerotic lesion size and vascular calcification. Arterioscler Thromb Vasc Biol 33:11 (2013), 2491–2500, 10.1161/ATVBAHA.113.301755.
11. Collin-Osdoby, P., Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 95:11 (2004), 1046–1057.
12. Collin-Osdoby, P., Rothe, L., Anderson, F., Nelson, M., Maloney, W., Osdoby, P., Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 276:23 (2001), 20659–20672, 10.1074/jbc.M010153200.
13. Condliffe, R., Pickworth, J.A., Hopkinson, K., Walker, S.J., Hameed, A.G., Suntharaligam, J., et al. Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension. Pulm Circ 2:1 (2012), 21–27, 10.4103/2045-8932.94819.
14. Cross, S.S., Yang, Z., Brown, N.J., Balasubramanian, S.P., Evans, C.A., Woodward, J.K., et al. Osteoprotegerin (OPG)—a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis?. Int J Cancer 118:8 (2006), 1901–1908, 10.1002/ijc.21606.
15. Emery, J., McDonnell, P., Burke, M., Deen, K., Lyn, S., Silverman, C., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273:23 (1998), 14363–14367.
16. Hameed, A.G., Arnold, N.D., Chamberlain, J., Pickworth, J.A., Paiva, C., Dawson, S., et al. Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension. J Exp Med 209:11 (2012), 1919–1935, 10.1084/jem.20112716.
17. Hoeper, M.M., Bogaard, H.J., Condliffe, R., Frantz, R., Khanna, D., Kurzyna, M., et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 62:25 Suppl (2013), D42–D50, 10.1016/j.jacc.2013.10.032.
18. Hofbauer, L., Schoppet, M., Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292:4 (2004), 490–495.
19. Hosbond, S.E., Poulsen, T.S., Diederichsen, A.C.P., Nybo, M., Rasmussen, L.M., Mickley, H., Osteoprotegerin as a marker of atherosclerosis: a systematic update. Scand Cardiovasc J 46:4 (2012), 203–211, 10.3109/14017431.2012.685491.
20. Humbert, M., Lau, E.M.T., Montani, D., Jais, X., Sitbon, O., Simonneau, G., Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation 130:24 (2014), 2189–2208, 10.1161/CIRCULATIONAHA.114.006974.
21. Hurdman, J., Condliffe, R., Elliot, C.A., Davies, C., Hill, C., Wild, J.M., et al. ASPIRE registry: assessing the spectrum of pulmonary hypertension identified at a referral centre. Eur Respir J 39:4 (2012), 945–955, 10.1183/09031936.00078411.
22. Karatolios, K., Pankuweit, S., Goettsch, C., Hofbauer, L.C., Timmesfeld, N., Al-Fakhri, N., et al. Osteoprotegerin (OPG) and TNF-related apoptosis-inducing ligand (TRAIL) levels in malignant and benign pericardial effusions. Clin Biochem 45:3 (2012), 237–242, 10.1016/j.clinbiochem.2011.12.003.
23. Kim, J., Song, T.-J., Yang, S.-H., Lee, O.-H., Nam, H.S., Kim, Y.D., et al. Plasma osteoprotegerin levels increase with the severity of cerebral artery atherosclerosis. Clin Biochem 46:12 (2013), 1036–1040, 10.1016/j.clinbiochem.2013.05.048.
24. Kobayashi-Sakamoto, M., Isogai, E., Hirose, K., Chiba, I., Role of αv integrin in osteoprotegerin-induced endothelial cell migration and proliferation. Microvasc Res 76:3 (2008), 139–144, 10.1016/j.mvr.2008.06.004.
25. Lane, D., Matte, I., Laplante, C., Garde-Granger, P., Rancourt, C., Piché, A., Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis. J Ovarian Res, 6(1), 2013, 82, 10.1186/1757-2215-6-82.
26. Lane, D., Matte, I., Rancourt, C., Piché, A., Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis. J Ovarian Res, 5(1), 2012, 34, 10.1186/1757-2215-5-34.
27. Lawrie, A., Waterman, E., Southwood, M., Evans, D., Suntharalingam, J., Francis, S., et al. Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. Am J Pathol 172:1 (2008), 256–264, 10.2353/ajpath.2008.070395.
28. Li, Y., Li, A., Yang, X., Weitzmann, M.N., Ovariectomy-induced bone loss occurs independently of B cells. J Cell Biochem 100:6 (2007), 1370–1375, 10.1002/jcb.21121.
29. McGonigle, J.S., Tae, G., Stayton, P.S., Hoffman, A.S., Scatena, M., Heparin-regulated delivery of osteoprotegerin promotes vascularization of implanted hydrogels. J Biomater Sci Polym Ed 19:8 (2008), 1021–1034, 10.1163/156856208784909381.
30. Morony, S., Tintut, Y., Zhang, Z., Cattley, R., Van, G., Dwyer, D., et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(−/−) mice., 117(3), 2008, 411–420, 10.1161/CIRCULATIONAHA.107.707380.
31. Mosheimer, B., Kaneider, N., Feistritzer, C., Djanani, A., Sturn, D., Patsch, J., Wiedermann, C., Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J Clin Endocrinol Metab 90:5 (2005), 2964–2971.
32. Mosheimer, B., Kaneider, N., Feistritzer, C., Sturn, D., Wiedermann, C., Expression and function of RANK in human monocyte chemotaxis. Arthritis Rheum 50:7 (2004), 2309–2316.
33. Olesen, M., Skov, V., Mechta, M., Mumm, B.H., Rasmussen, L.M., No influences of OPG and its ligands, RANKL and TRAIL, on proliferation and regulation of the calcification process in primary human vascular smooth muscle cells. Mol Cell Endocrinol, 2012, 10.1016/j.mce.2012.06.004.
34. Olesen, P., Ledet, T., Rasmussen, L.M., Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia 48:3 (2005), 561–568, 10.1007/s00125-004-1652-8.
35. Pérez de Ciriza, C., Lawrie, A., Varo, N., Osteoprotegerin in cardiometabolic disorders. Int J Endocrinol, 2015(3), 2015, 10.1155/2015/564934 (564934–15).
36. Pritzker, L.B., Scatena, M., Giachelli, C.M., The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell 15:6 (2004), 2834–2841, 10.1091/mbc.E04-01-0059.
37. Rasmussen, L., Tarnow, L., Hansen, T., Parving, H., Flyvbjerg, A., Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 154:1 (2006), 75–81.
38. Schoppet, M., Kavurma, M.M., Hofbauer, L.C., Shanahan, C.M., Crystallizing nanoparticles derived from vascular smooth muscle cells contain the calcification inhibitor osteoprotegerin. Biochem Biophys Res Commun 407:1 (2011), 103–107, 10.1016/j.bbrc.2011.02.117.
39. Secchiero, P., Gonelli, A., Carnevale, E., Corallini, F., Rizzardi, C., Zacchigna, S., et al. Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand. Neoplasia 6:4 (2004), 364–373, 10.1593/neo.03421.
40. Simonet, W., Lacey, D., Dunstan, C., Kelley, M., Chang, M., Luthy, R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density., 89(2), 1997, 309–319, 10.1016/S0092-8674(00)80209-3.
41. Stępień, E., Wypasek, E., Stopyra, K., Konieczyńska, M., Przybyło, M., Pasowicz, M., Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin) in hypertensive individuals. Clin Biochem 44:10-11 (2011), 826–831, 10.1016/j.clinbiochem.2011.04.016.
42. Tanaka, H., Mine, T., Ogasa, H., Taguchi, T., Liang, C.T., Expression of RANKL/OPG during bone remodeling in vivo. Biochem Biophys Res Commun 411:4 (2011), 690–694, 10.1016/j.bbrc.2011.07.001.
43. Tsuda, E., Goto, M., Mochizuki, S., Yano, K., Kobayashi, F., Morinaga, T., Higashio, K., Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234:1 (1997), 137–142.
44. Tuder, R.M., Archer, S.L., Dorfmüller, P., Erzurum, S.C., Guignabert, C., Michelakis, E., et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 62:25 Suppl (2013), D4–12, 10.1016/j.jacc.2013.10.025.
45. Ueland, T., Jemtland, R., Godang, K., Kjekshus, J., Hognestad, A., Omland, T., et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 44:10 (2004), 1970–1976, 10.1016/j.jacc.2004.06.076.
46. Ueland, T., Kjekshus, J., Frøland, S.S., Omland, T., Squire, I.B., Gullestad, L., et al. Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patients. J Am Coll Cardiol 46:11 (2005), 2018–2021, 10.1016/j.jacc.2005.08.039.
47. Ueland, T., Yndestad, A., Dahl, C.P., Gullestad, L., Aukrust, P., TNF revisited: osteoprotegerin and TNF-related molecules in heart failure. Curr Heart Fail Rep 9:2 (2012), 92–100, 10.1007/s11897-012-0088-6.
48. Vitovski, S., Phillips, J., Sayers, J., Croucher, P., Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem 282:43 (2007), 31601–31609.
49. Whyte, M.P., Obrecht, S.E., Finnegan, P.M., Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 347:3 (2002), 175–184, 10.1056/NEJMoa013096.
50. Yamaguchi, K., Kinosaki, M., Goto, M., Kobayashi, F., Tsuda, E., Morinaga, T., Higashio, K., Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem 273:9 (1998), 5117–5123, 10.1074/jbc.273.9.5117.
51. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95:7 (1998), 3597–3602.
52. Zauli, G., Corallini, F., Bossi, F., Fischetti, F., Durigutto, P., Celeghini, C., et al. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 110:2 (2007), 536–543, 10.1182/blood-2007-01-068395.
53. Zauli, G., Melloni, E., Capitani, S., Secchiero, P., Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci 66:5 (2009), 841–851, 10.1007/s00018-008-8536-x.
54. Ziegler, S., Kudlacek, S., Luger, A., Minar, E., Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 182:1 (2005), 175–180.